Dengue fever

• 1. Introduction

  ›

  Dengue fever is a mosquito-borne disease that infects billions of people around the world, caused by a virus with four distinct forms that behave almost like different enemies. In 2023 alone, more than 5 million infections were reported, and more than 5,000 people died. Those numbers almost certainly undercount the true toll, because most cases are so mild they never appear in any official record.

  What makes dengue unusual is a cruel biological twist: surviving one form of the virus does not protect you from the others. A second infection with a different strain can actually make your body's immune defenses turn against you, driving the disease from a bad flu into a life-threatening emergency. That paradox sits at the heart of why dengue remains one of the hardest diseases on earth to control.

  How does a single mosquito bite trigger a cascade that can cause organs to fail? Why does the World Health Organization estimate that 3.9 billion people are currently at risk? And what does the name itself reveal about how people throughout history have experienced this illness? Those questions, and the surprising history behind them, are what this documentary explores.

• 2. The Virus and Its Four Faces

  ›

  Dengue virus belongs to the family Flaviviridae, a group that also includes yellow fever virus, West Nile virus, and Zika virus. Its genome contains about 11,000 nucleotide bases, encoding three structural proteins that form the virus particle and seven more required for replication. That compact genetic package exists in four confirmed forms, known as serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, distinguished from one another by their antigenicity.

  The four-serotype structure is what gives dengue its unusual danger profile. After a first infection, the immune system builds lifelong protection against that specific serotype. For the other three, however, the protection is only temporary. When a person encounters a second serotype later, a process called antibody-dependent enhancement, or ADE, can occur.

  In ADE, the antibodies produced during the first infection do recognize the new virus, but they fail to neutralize it. Instead, the antibody-virus complex binds more easily to receptors on immune cells, actually helping the virus enter and replicate inside the very cells meant to fight it. The exact mechanism is not fully understood, but the consequence is measurable: a second dengue infection dramatically raises the risk of developing severe disease.

  Areas where more than one serotype circulates simultaneously are described as hyperendemic, and people living there face compounding danger with each successive exposure. The disease is already endemic in more than 100 countries, and its reach is growing.

• 3. How the Body Breaks Down

  ›

  A single bite from an infected mosquito deposits the virus directly into the skin, where it infects keratinocytes and specialized immune cells called Langerhans cells. Those Langerhans cells then migrate toward the lymph nodes, carrying the infection with them. From there, the virus spreads into white blood cells and travels through the body inside the very cells dispatched to contain it.

  The febrile phase brings fever reaching 40-41 degrees Celsius, along with generalized pain, headache, nausea, vomiting, and the characteristic pain behind the eyes. This phase typically lasts two to seven days. Most people recover in a week or so, and the recovery phase often arrives suddenly, sometimes accompanied by intense itching and a slowing heart rate.

  In roughly 5% of cases, however, the disease shifts into a critical phase. Plasma leaks through the walls of small blood vessels into body cavities. Blood volume falls, and pressure drops to the point where vital organs cannot receive adequate supply. The bone marrow is affected, reducing the production of platelets needed for clotting, which compounds the bleeding risk.

  For a pregnant woman, dengue carries additional consequences: higher risk of miscarriage, low birth weight, and premature birth. Children under five years old face a fatality rate four times higher than those over ten. Among adults, older age, female sex, high body mass index, and underlying conditions such as diabetes or sickle cell anemia all raise the risk of a severe outcome. Among patients who develop significantly low blood pressure, the fatality rate can reach 26%.

• 4. The Mosquito at the Center

  ›

  Aedes aegypti is the principal vector of dengue, and its biology shapes the entire geography of the disease. The species prefers to feed at dusk and dawn, though it can bite at any hour. After taking a blood meal from an infected host, the female mosquito carries a high concentration of dengue virus in her blood for 2 to 10 days. The virus moves from her gut to her salivary glands over the following days, and from that point she can infect every person she bites for the rest of her life. The virus appears to cause her no harm at all.

  Three other Aedes species can also transmit the virus: A. albopictus, A. polynesiensis, and A. scutellaris. Both A. aegypti and A. albopictus are expanding their ranges. Between 2010 and 2019, the WHO recorded a tenfold increase in reported dengue cases, from 500,000 to 5 million, a rise attributed to urbanization, population growth, and a warming climate.

  In October 2023, the first confirmed symptomatic case of locally acquired dengue in the United States was identified in California, a marker of just how far the disease's reach has extended beyond its traditional boundaries in Southeast Asia and the Americas.

• 5. Prevention, Vaccines, and Treatment

  ›

  Controlling Aedes aegypti means eliminating the small bodies of standing water where it breeds. Buckets, planters, trashcans, blocked gutters, and uncovered pools can all serve as breeding sites. Generalized spraying with organophosphate or pyrethroid insecticides is not considered effective, and environmental modification is preferred. DEET remains the most effective personal repellent. Treating clothing, nets, and tents with 0.5% permethrin adds an additional layer of protection.

  As of March 2024, two vaccines exist. Dengvaxia, formerly known as CYD-TDV, became available in 2015 and is approved in the US, the EU, and several Asian and Latin American countries. It covers all four serotypes and is given as three doses at six-month intervals, but safety concerns about ADE mean it should only be administered to people who have already been infected. Sanofi-Pasteur, the manufacturer, has stated it will cease producing Dengvaxia during 2026 due to insufficient global demand.

  Qdenga, formerly TAK-003, completed clinical trials in 2022 and was approved in the European Union in December 2022. Unlike Dengvaxia, it can be given to people with no prior dengue infection, is indicated for those four years old and older, and is administered as two doses three months apart. The WHO's SAGE committee has recommended it. The Philippines expanded a pilot vaccination program using Qdenga to major urban centers in 2025 and 2026 following promising early results.

  As of July 2024, no specific antiviral drug exists for dengue. Acetaminophen can manage mild pain and fever, but aspirin, ibuprofen, and naproxen must be avoided because they increase bleeding risk. Severe cases require hospitalization, intravenous fluids, and sometimes transfusions of platelets or plasma. With adequate treatment, the death rate among severe dengue patients falls below 1%.

• 6. A Name Rooted in History

  ›

  The word dengue entered English in the early 19th century by a winding route. It came from West Indian Spanish, which had borrowed the term from the Kiswahili dinga or denga, meaning "cramp-like seizure." The full Kiswahili phrase was ki-dinga pepo, describing the condition as a cramp-like seizure caused by an evil spirit.

  When the word crossed into Spanish, it blended with an existing Spanish word meaning "fastidiousness," a coincidence that generated a folk etymology: the disease made movement so painful that patients were reluctant to move at all. West Indian enslaved people who contracted dengue were observed to carry themselves with an exaggerated, stiff posture, and the disease picked up the nickname "dandy fever" because their gait resembled that of a dandy.

  Physician and United States Founding Father Benjamin Rush applied a different name. In a 1789 report on the 1780 epidemic in Philadelphia, he called it "break-bone fever" because of the severe muscle and joint pains, though his formal report title used the term "bilious remitting fever." The phrase dengue fever did not enter general use until after 1828.

  The earliest record of a probable dengue outbreak predates all of these names by more than a millennium: a Chinese medical encyclopedia from the Jin dynasty, covering 266 to 420, described a "water poison" associated with flying insects. The principal mosquito vector, Aedes aegypti, spread out of Africa between the 15th and 19th centuries, carried by the slave trade and the expansion of international commerce. Epidemics in Jakarta, Cairo, and Philadelphia during the 18th century are now believed to have been caused by dengue. The severe hemorrhagic form of the disease was first identified in the Philippines in 1953, and by the 1970s it had been recognized as a leading cause of child mortality across Southeast Asia.

• 7. A Global Burden Still Growing

  ›

  A study estimated the global economic burden of dengue in 2013 at US$8.9 billion, accounting for medical costs, lost productivity, and the persistent symptoms that linger after the acute phase ends. That figure represents a disease then primarily confined to tropical and subtropical regions. Since then the geographic footprint has continued to shift.

  Dengue is now spreading onto the Iberian Peninsula and into the southern United States, patterns linked in part to climate change. Rising temperatures accelerate the mosquito's life cycle, increase its biting frequency, and shorten the time the virus needs to become infectious inside the mosquito. Changes in rainfall create more standing water, particularly in dense urban areas. Warmer conditions allow Aedes mosquitoes to establish themselves at higher altitudes and in temperate zones that were previously outside their range.

  International Anti-Dengue Day is observed every year on the 15th of June. The idea was agreed upon in 2010, with the first event held in Jakarta, Indonesia, in 2011. Subsequent events took place in Yangon, Myanmar, in 2012 and in Vietnam in 2013. India holds a National Dengue Day each year on the 16th of May. The Philippines has maintained a dengue awareness month every June since 1998.

  Active research continues on antiviral drugs targeting the NS3 or NS5 proteins of the dengue virus, on Organ Chips and Lab-on-Chips as experimental models for dengue leak syndrome, and on additional vaccine candidates beyond the two already approved. Each year that passes without a cure, the 3.9 billion people the WHO estimates are currently at risk remain exposed to a disease that is still, by the WHO's own classification, a neglected tropical disease.